
Medicus Pharma’s Teverelix has demonstrated long-lasting hormone suppression, as well as a favourable safety profile, in new study data. Teverelix …
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board

